Golodirsen: First Approval
Sign Up to like & getrecommendations! Published in 2020 at "Drugs"
DOI: 10.1007/s40265-020-01267-2
Abstract: Golodirsen (Vyondys 53 ™ ), an antisense oligonucleotide of the phophorodiamidate morpholino oligomer (PMO) subclass designed to induce exon 53 skipping, has been developed by Sarepta Therapeutics for the treatment of Duchenne muscular dystrophy (DMD).… read more here.
Keywords: dmd; first approval; treatment; golodirsen ... See more keywords